Chief Financial Officer · EAGLE PHARMACEUTICALS, INC. (EGRX)

Brian Cahill

A named executive officer of EAGLE PHARMACEUTICALS in every fiscal year CompBrief holds from FY2020 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$2,493,347

Salary $394,908Stock awards $1,787,283

FY2021: $1,855,611

3rd of 3 named executive officers at Eagle Pharmaceuticals by FY2022 total.

3 named officers on file for EAGLE PHARMACEUTICALS, FY2022

Brian Cahill’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 9 equity grants, each cited to its filing
  • EGRX’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how EAGLE PHARMACEUTICALS’s whole pay program stands against its peers

  • EAGLE PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on EGRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 1, 2023 (DEF 14A).

Free

Get Brian Cahill’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Brian Cahill compensation by year

EAGLE PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as EAGLE PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022
Salary$334,880$380,000$394,908
Bonus$0$0$0
Stock awards$658,980$1,071,649$1,787,283
Option awards$655,111$0$0
Non-equity incentive$136,050$373,920$177,840
Pension and deferred compensation$0$0$0
All other$29,307$30,042$33,316
Total$1,814,328$1,855,611$2,493,347

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: EAGLE PHARMACEUTICALS, INC. DEF 14A filed May 1, 2023, accession 0001104659-23-054338, and prior-year filings.

How this page was built: the EAGLE PHARMACEUTICALS, INC. filed document, accession 0001104659-23-054338. Every figure is read from that document and cited to the page and table it appears in. Filed May 1, 2023.

$1.8M
$1.9M
$2.5M
FY20
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
PSU24,100$704,443—
PSU8,900$453,188—
PSU7,600$386,992—
RSU8,000$233,840—
RSU6,675$195,110—
RSU3,500$102,305—
RSU2,500$73,075—
RSU1,704$49,808—
Option4,583—$48.09
Option3,521—$59.79
Option284—$41.37

Per the Outstanding Equity Awards at Fiscal Year-End table in EAGLE PHARMACEUTICALS, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments EAGLE PHARMACEUTICALS discloses, by trigger · FY2022
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Change in control, no termination$0$1,825,046$0$1,825,046
Death$0$0$0$0
Involuntary termination without cause$0$0$0$0
Change in control and involuntary termination$0$1,825,046$0$1,825,046
Resignation for good reason, no change in control$0$0$0$0
Change in control and resignation for good reason$0$1,825,046$0$1,825,046
Disability$0$0$0$0

Per the Potential Payments Upon Termination or Change in Control table in EAGLE PHARMACEUTICALS, INC.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.

EAGLE PHARMACEUTICALS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Scott TarriffPresident, Chief Executive Officer, Director$10,520,577
Michael MoranFormer Chief Commercial Officer$2,608,325
Brian Cahill · this pageChief Financial Officer$2,493,347

The full EAGLE PHARMACEUTICALS compensation record

free company brief

This page is one person within EAGLE PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the EAGLE PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are EAGLE PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Brian Cahill's compensation dossier · One-time report. No refunds.